Open AccessThe Expression Changes of CX3CL1 and Interlukin-6 Genes During Remission Induction Therapy in Patients With Acute Myeloid Leukemia
Author(s) -
Mahdiyar Iravani Saadi,
Mani Ramzi,
Aliasghar Karimi,
Maryam Owjfard,
Mahmoud Torkamani,
Nadiya Kheradmand,
Ahmad Niknam,
Zahed Karimi,
Mohammad Kazem Vakil,
Mohammad Hosein Yazdanpanah
Publication year - 2021
Publication title -
galen medical journal
Language(s) - English
Resource type - Journals
eISSN - 2588-2767
pISSN - 2322-2379
DOI - 10.31661/gmj.v10i0.2288
Subject(s) - medicine , myeloid leukemia , chemotherapy , induction chemotherapy , cx3cl1 , oncology , myeloid , leukemia , immunology , malignancy , cancer research , gastroenterology , inflammation , chemokine , chemokine receptor
Background: Acute Myeloid Leukemia syndrome (AML) is a hematologic malignancy which is due to clonal extensive proliferation of leukemic precursor cells and is rapidly fatal unless treated or response to chemotherapy. Cytogenetic findings have important role in prognosis and categorization of AML. The aim of this study was to investigate the expression changes in CX3CL1 and Interlukin-6 (IL-6) genes before and after chemotherapy as remission induction therapy in AML patients. Materials and Methods: In this study 69 patients (36 males, 33 female) with AML was selected from tertiary medical heath center. A quantitative polymerase chain reaction (PCR) was done for mRNA expression of CX3CL1 and IL-6genes before and after induction chemotherapy. To obtain expression changes in CX3CL1 and IL-6genes, we used 2-ΔΔCT method. Results: The expression of CX3CL1 and IL-6 was significantly increased after induction chemotherapy. Also, the ΔCt mean of CX3CL1 and IL-6 mRNA was not significant between AML subtype groups. Conclusion: In conclusion, as we showed that chemotherapy significantly increase the expression of CX3CL1 and IL-6 which can be used as a prognostic factor of AML.